# Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

> **NCT01447914** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 16 (actual)

## Conditions studied

- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Tivantinib
- **OTHER:** Diagnostic laboratory biomarker analysis
- **OTHER:** Questionnaire administration
- **PROCEDURE:** Quality-of-life assessment

## Key facts

- **NCT ID:** NCT01447914
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2014-03
- **Final completion:** 2014-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01447914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01447914, "Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01447914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*